Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cue Biopharma, Inc.

CUE ✓ COMPLIANT ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$34.17

▲ +8.00%

Market Cap $248.23M · Vol 81.01K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$248.23M

Micro Cap

Div Yield

N/A

EPS Growth

-155.42%

YoY

RSI (14)

63.04

Momentum

Beta

2.56

vs Market

52W High

$45.23

24.45% below

52W Low

$4.97

586.97% above

Volume

81.01K

Avg 39.27K

P/B

1.12

Price-to-book

ROE

N/A

Return on equity

Free Float

90.30%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cue Biopharma, Inc. (CUE) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CUE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+12.03%

-0.09%

+43.03%

+265.65%

YTD

+272.95%

+53.30%

-55.51%

-90.90%

Financials & Valuation

TTM · Annual

Total Revenue	$27.47M
Net Income	$-26,602,000.00
Revenue Growth (YoY)	+166.66%
Gross Margin	100.00%
Operating Margin	-96.56%
Net Profit Margin	-96.85%
ROE	N/A
ROA · ROIC	-70.16% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.05
P/B	1.12
P/FCF	N/A
EPS Growth	-155.42%
Outstanding Shares	7.26M

Technical Indicators

50-Day SMA	$29.34
200-Day SMA	$19.27
RSI (14)	63.04
Beta	2.56
52-Week High	$45.23
52-Week Low	$4.97

Volume Today	81.01K
Avg Daily Volume (30D)	39.27K
Relative Volume	2.06x
Volatility (10D)	82.66
Volatility (30D)	113.81
Free Float	90.30%

Analyst Consensus

STRONG BUY

Current Price $34.17

Mean Target $90.50

52W Low$4.97 52W High$45.23

Current

Target

$4.97 $45.23

Current Analyst target

+164.85% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00FVMPFP5

ISINUS22978P2056

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +0.57% ARGX.BR argenx SE -1.19% ARGX argenx SE +0.50% INSM Insmed Incorporated +2.22% 2269.HK WuXi Biologics (Cayman) Inc. +1.46%

Company Profile

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.